COMPASS Pathways plc

CMPSSEC EDGAR

Pharmaceutical Preparations(X0)CIK: 1816590

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$87.5M	$44.0M	$23.4M	$12.6M	$12.6M
Operating Expenses	$136.9M	$83.2M	$51.4M	$21.2M	$21.2M
Operating Income (Loss)	-$136.9M	-$83.2M	-$51.4M	-$21.2M	-$21.2M
Interest Expense	—	$0.00	—	—	—
Nonoperating Income (Expense)	$19.2M	$11.7M	-$8.9M	$1.6M	$1.6M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$117.7M	-$71.5M	-$60.3M	-$19.6M	—
Income Tax Expense (Benefit)	$780.0K	$199.0K	$32.0K	$15.0K	$15.0K
Net Income (Loss) Attributable to Parent	-$118.5M	-$71.7M	-$60.3M	-$19.6M	-$19.6M
Earnings Per Share, Basic	-$2.32	-$1.79	-$3.55	-$2.62	—
Earnings Per Share, Diluted	-$2.32	-$1.79	-$3.55	-$2.62	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$276.0M	$197.3M	$300.9M	$203.5M	$32.4M
Assets, Current	$261.3M	$191.7M	$295.3M	$202.4M	$32.2M
Cash and Cash Equivalents, at Carrying Value	$220.2M	$273.2M	$190.3M	$25.0M	$25.0M
Liabilities	$50.2M	$16.0M	$16.5M	$6.9M	$23.9M
Liabilities, Current	$19.6M	$15.6M	$15.1M	$6.9M	$23.9M
Long-term Debt	$30.2M	$0.00	—	—	—
Accounts Payable, Current	$5.9M	$4.8M	$2.6M	$2.7M	$1.3M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$97.4M	-$67.7M	-$41.4M	-$17.8M	-$17.8M
Net Cash Provided by (Used in) Investing Activities	-$64.0K	-$334.0K	-$628.0K	-$165.0K	-$165.0K
Net Cash Provided by (Used in) Financing Activities	$173.8M	$156.6M	$194.2M	$18.4M	$18.4M
Payments to Acquire Property, Plant, and Equipment	$66.0K	$334.0K	$131.0K	$165.0K	$165.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)